Company profile: Detraxi
1.1 - Company Overview
Company description
- Provider of proprietary biotechnology solutions addressing blood and organ shortages, including alternatives to whole or derived blood products aimed at eliminating the need for donations; technologies to preserve and regenerate organs outside the body to extend transplant viability; regenerative medicine to engineer organs and reduce reliance on donated tissues; and enhanced diagnostics to better preserve samples and improve test accuracy.
Products and services
- Ending The Organ Donation Crisis: Detraxi architects an outside-the-body technology that preserves and regenerates organs, extending viability and availability for transplantation to mitigate the organ donation crisis
- Ending The Global Blood Shortage: Detraxi engineers a biotechnology-based product that eliminates reliance on blood donations by supplying an alternative to whole or derived blood products, targeting the global blood shortage
- Regenerative Medicine: Detraxi advances proprietary regenerative medicine focused on engineering and regenerating organs outside the body to treat diseases and reduce reliance on donated tissues
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Detraxi
Greyson
HQ: United States
Website
- Description: Provider of health and beauty aid products, engaging in their research, development, and marketing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Greyson company profile →
Sarissa Biomedical
HQ: United Kingdom
Website
- Description: Provider of minimally invasive microelectrode electrochemical biosensors that detect purines and other neurochemicals, such as serotonin and dopamine, in blood to aid diagnosis and monitoring of neurological disorders. Solutions offer exquisite sensitivity, broad linear range, rapid measurements, and high accuracy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sarissa Biomedical company profile →
Standard BioTools
HQ: United States
Website
- Description: Provider of microfluidic-based chips and instrumentation for biological research as a biotech tools company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Standard BioTools company profile →
Neothetics
HQ: United States
Website
- Description: Provider of clinical-stage specialty pharmaceutical therapeutics for the aesthetic market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neothetics company profile →
Magnolia Medical
HQ: United States
Website
- Description: Provider of blood culture contamination reduction solutions, including Steripath Initial Specimen Diversion Device and Steripath Micro to divert and sequester initial blood draws, the Mission Control educational platform offering best-practice collection training, and a clinical performance guarantee of at least 50% contamination reduction or money back.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Magnolia Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Detraxi
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Detraxi
2.2 - Growth funds investing in similar companies to Detraxi
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Detraxi
4.2 - Public trading comparable groups for Detraxi
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →